Ainnova Tech Inc. and Avai Bio, Inc. entered into a mutual termination agreement.
On May 7, 2026, Ainnova Tech Inc. and Avai Bio, Inc. entered into a mutual termination agreement. The agreement was disclosed in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission.
Ainnova remains focused on its core mission — advancing AI-powered early disease detection through VisionAI and its portfolio of preventive-health solutions.
Avaí Bio, Inc. (OTCQB: AVAI) is a biotechnology company — formerly known as Avant Technologies — focused on developing cell-based therapies, including an α-Klotho anti-aging program and work in diabetes.
The mutual termination concludes the prior arrangement between the two companies.
Ainnova Tech is a healthcare technology company focused on revolutionizing early disease detection using artificial intelligence. Its platform, VisionAI, analyzes retinal images to detect early markers of diseases such as diabetic retinopathy — with a growing portfolio spanning cardiovascular, metabolic, liver and kidney risk. Ainnova is dedicated to making healthcare more proactive, accessible and efficient.
Source: SEC Form 8-K ↗
Contact: Ainnova Tech — info@ainnovatech.com